Status:
TERMINATED
Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Cataract
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
The objective of this study is to demonstrate the correlation of near vision and changes in higher order aberrations following lens extraction and to characterize the defocus curves of Crystalens® AO™...
Eligibility Criteria
Inclusion
- Subjects must have clear intraocular media other than cataract.
- Subjects must have a clinically documented diagnosis of age-related bilateral cataracts that are considered amenable to treatment with standard phacoemulsification cataract extraction.
- Subjects must be undergoing primary IOL implantation for the correction of aphakia following central continuous curvilinear anterior capsulorrhexis and phacoemulsification cataract extraction.
- Subjects must require a spherical lens power from 10.00 D to 30.00 D.
- Subjects must be willing and able to return for all scheduled follow-up examinations for each eye from days 1 through 180 following surgery.
- Subjects must have ≤ 1.25 D of preoperative corneal astigmatism.
Exclusion
- Subjects with corneal pathology potentially affecting topography.
- Subjects whose fundus cannot be assessed preoperatively.
- Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level worse than 20/30 as verified by OCT.
- Subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome.
- Subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.
- Subjects with uncontrolled glaucoma.
- Subjects with previous retinal detachment.
- Subjects with visually significant diabetic retinopathy (proliferative or non-proliferative) which reduces potential acuity to 20/30 or worse.
- Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.
- Subjects with marked microphthalmos or aniridia.
- Subjects who have had previous corneal surgery.
- Subjects with irregular corneal astigmatism.
- Subjects with amblyopia which reduces potential acuity to worse than 20/30.
- Subjects with optic atrophy.
- Subjects with iris neovascularization.
- Subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/30 or worse.
- Subjects with chronic use of systemic steroids or immunosuppressive medications.
- Subjects lacking intact binocular vision.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01241279
Start Date
October 1 2010
End Date
December 1 2011
Last Update
November 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch & Lomb
Irvine, California, United States, 92618